Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib
Clinical trial NCT03725072 · COMPLETED
Trial details
- NCT number
- NCT03725072
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-30
- Primary completion
- 2018-12-05
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.